Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Forma Therapeutics Holdings Inc is a biotechnology business based in the US. Forma Therapeutics shares (FMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Forma Therapeutics employs 176 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $7.12 |
|---|---|
| 52-week range | $4.95 - $26.61 |
| 50-day moving average | $6.65 |
| 200-day moving average | $12.73 |
| Wall St. target price | $40.29 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.82 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.12 from 2022-07-01
| 1 week (2022-06-24) | 1.28% |
|---|---|
| 1 month (2022-06-03) | 23.18% |
| 3 months (2022-04-01) | -28.73% |
| 6 months (2022-01-03) | -51.53% |
| 1 year (2021-07-02) | -71.30% |
|---|---|
| 2 years (2020-07-02) | -85.27% |
| 3 years (2019-06-29) | N/A |
| 5 years (2017-06-29) | N/A |
| Revenue TTM | $7.4 million |
|---|---|
| Gross profit TTM | $-125,661,000 |
| Return on assets TTM | -19.55% |
| Return on equity TTM | -33.62% |
| Profit margin | 0% |
| Book value | $9.66 |
| Market capitalisation | $353.7 million |
TTM: trailing 12 months
We're not expecting Forma Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Forma Therapeutics's shares have ranged in value from as little as $4.95 up to $26.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Forma Therapeutics's is 0.4367. This would suggest that Forma Therapeutics's shares are less volatile than average (for this exchange).
Forma Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.